Skip to main
GERN
GERN

Geron (GERN) Stock Forecast & Price Target

Geron (GERN) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 6%

Bulls say

Geron Corp's recent approval of Rytelo (imetelstat) in the European Union for treating low-risk myelodysplastic syndrome (LR-MDS) is expected to enhance potential revenue streams starting in 2026, aligning with previous expectations. The company maintains a strategic focus on educating healthcare providers to drive the therapy's sales, which could significantly diversify revenue beyond previous sales dominated by third-line therapies. Additionally, the confidence expressed by the board and leadership in the therapeutic potential of imetelstat, particularly its demonstrated effectiveness in disease modification for LR-MDS, reinforces a positive outlook for Geron's long-term financial performance.

Bears say

The financial outlook for Geron Corp is notably negative due to a trend of flat revenues that may persist for an extended period, delaying any potential recovery or growth. Additionally, the postponement of pivotal IMpactMF trial results to the second half of 2026 signifies a lack of near-term value-creating events, further contributing to investor concerns. Key risks, including safety signals from clinical programs, lower-than-expected efficacy, increased competition, regulatory hurdles, and potential failures in intellectual property protection, compound the uncertainties surrounding the company's future performance.

Geron (GERN) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geron (GERN) Forecast

Analysts have given Geron (GERN) a Buy based on their latest research and market trends.

According to 18 analysts, Geron (GERN) has a Buy consensus rating as of Sep 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.01, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.01, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geron (GERN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.